Could a diabetes combo drug melt liver fat better than insulin alone?
NCT ID NCT07274644
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a combination diabetes drug (iGlarLixi) against insulin alone to see which better reduces liver fat in people with type 2 diabetes and a common fatty liver condition called MASLD. About 36 participants will take one of the two treatments for 12 weeks, and doctors will measure liver fat using MRI scans. The goal is to find a more effective way to manage both blood sugar and liver health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iGlarLixi (a combination of insulin glargine and lixisenatide)
What this could lead to
If successful, this could show that iGlarLixi is a better option than insulin alone for reducing liver fat in people with type 2 diabetes and fatty liver disease.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply to everyone. The study is also open-label, meaning both patients and doctors know which treatment is given, which can introduce bias.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210008, China